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The role of anemia and vitamin D levels in acute and
chronic telogen effluvium
Ayşe Serap KARADAĞ1, Derun Taner ERTUĞRUL2, Emre TUTAL3, Kadir Okhan AKIN4

Aim: Telogen effluvium (TE) is an abnormality of hair cycling. Vitamin D promotes hair follicle differentiation. The
importance of vitamin D in hair growth is evident in patients with hereditary vitamin D receptor deficiency. The role
of vitamin D in the pathogenesis of TE has not been investigated before. We investigated the role of vitamin D, ferritin,
and zinc in the pathogenesis of TE.
Materials and methods: We measured serum hemoglobin, ferritin, zinc, calcium, phosphate, parathormone,
magnesium, 25 and 1,25-hydroxyvitamin D3, and bone alkaline phosphatase and thyroid stimulating hormone levels in
63 female patients and 50 control subjects. Twenty-nine of the TE patients were classified in the acute TE group and 34
were classified in the chronic TE groups.
Results: Ferritin (acute TE; 17.0 ± 12.8, chronic TE; 19.6 ± 15.2, control; 35.5 ± 31.8, P < 0.001) and hemoglobin (acute
TE; 12.7 ± 1.7, chronic TE; 13.3 ± 1.0, control; 14.2 ± 1.2, P < 0.0001) levels were significantly lower in the TE group
than in the control group. However, 25-hydroxyvitamin D3 levels were significantly higher in the TE group than in the
control group (acute TE; 18.5 ± 9.2, chronic TE; 24.4 ± 11.2, control; 15.6 ± 15.8, P < 0.01). Vitamin D levels increased
gradually from control groups to acute and chronic TE groups. However, active D vitamin levels (1,25-hydroxyvitamin
D3) were similar.
Conclusion: Iron deficiency anemia seems to be the main triggering factor for the development of TE and the increase
in serum 25-hydroxyvitamin D3 levels may be related to increased exposure to UV light due to TE.
Key words: Alopecia, hair disorder, telogen effluvium, vitamin D

Akut ve kronik telojen effluviumda anemi ve vitamin D seviyelerinin rolü
Amaç: Telojen effluvium (TE) bir saç siklus anomalisidir. Vitamin D kıl folikül farklılaşmasını destekler. Herediter
vitamin D reseptör eksikliği olan hastalarda saç gelişiminde vitamin D’nin önemi açıkca görülmektedir. TE’nin
patogenezinde vitamin D’nin rolü daha önce araştırılmamıştır. Biz TE’nin patogenenzinde vitamin D, ferritin ve
çinkonun rolünü araştırmaktayız.
Yöntem ve gereç: 63 bayan hasta ve 50 kontrolde ferritin, çinko, kalsiyum, fosfat, parathormon, magnezyum, 25 ve
1,25 hidroksi vitamin D3 ve kemik alkalen fosfataz düzeyi ölçüldü. TE hastalarının 29’u akut, 34’ü kronik TE olarak
sınıflandırıldı.
Bulgular: Ferritin (akut TE; 17,0 ± 12,8, kronik TE; 19,6 ± 15,2, kontrol; 35,5 ± 31,8, P < 0,001) ve hemoglobin (akut
TE; 12,7 ± 1,7, kronik TE; 13,3 ± 1,0, kontrol; 14,2 ± 1,2, p < 0,0001) seviyeleri kontrol grubu ile karşılaştırıldığında TE
grubunda belirgin olarak daha düşük bulundu. Buna rağmen 25-hidroksvitamin D3 seviyeleri TE grubunda kontrol
grubuna göre belirgin olarak daha yüksek bulundu (akut TE; 18,5 ± 9,2, kronik TE; 24,4 ± 11,2, kontrol; 15,6 ± 15,8, P
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< 0,01).Vitamin D seviyeleri sırasıyla kontrol grubu, akut ve kronik TE gruplarında giderek artmaktaydı. Buna rağmen
aktif vitamin D (1,25 -hidroksivitamin D3) seviyeleri benzerdi.
Sonuç: Demir eksikliği anemisi TE gelişiminde ana tetikleyici faktör olarak görülmektedir. 25- hidroksi vitamin D3
artışı da TE sonrası artan UV ışın maruziyetine bağlı olabilir.
Anahtar sözcükler: Alopesi, saç hastalığı, telojen effluvium, vitamin D

Introduction
Telogen effluvium (TE) is an abnormality of hair
cycling that results in excessive loss of telogen hairs
and is one of the most common causes of diffuse hair
loss (1). TE may be caused by thyroid disease, drugs,
and childbirth; however, in many cases etiology
could not be found (1). TE can be classified into acute
and chronic forms. Acute TE was first described as
an acute onset scalp hair loss, 2-3 months after a
triggering event, such as a high fever, or surgical
trauma, sudden starvation, and hemorrhage (2,3).
Severe iron-deficiency anemia and metabolic
disturbances, such as liver disorders and chronic
renal failure, are also known to cause sparse scalp hair
(3,4). In about 33% of cases of acute TE, triggering
pathological condition could not be identified and
the functional mechanism of shedding is supposed
to be secondary to an immediate anagen release (5).
Chronic telogen effluvium (CTE) was defined as a
primary idiopathic disease entity in 1996 (6). Women
suffering from CTE present with an abrupt onset of
generalized shedding of telogen hairs from the scalp,
with or without an identifiable trigger, that persists
for more than 6 months (7).
The main role of vitamin D until recent years was
considered to regulate calcium and bone metabolism.
However, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]
exerts many other important physiological effects,
including immunoregulation and protection against
UV radiation, infectious agents, oxidative stress,
and cancer (8). Vitamin D promotes hair follicle
differentiation, without affecting proliferation. The
importance of vitamin D in hair growth is evident in
patients with hereditary vitamin D receptor (VDR)
deficiency (vitamin D-dependent rickets type II),
who may suffer from alopecia (9). This role was also
demonstrated by Vegesna et al. in nude mice, as
application of vitamin D led to a dramatic stimulation
of hair growth, associated with increased expression
of several hair keratins (10).
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Iron deficiency is one of the most common
nutritional deficiencies that can be encountered
in daily practice. In premenopausal women, the
most common causes of iron deficiency anemia
are menstrual blood loss and pregnancy (11).
Hemoglobin concentration can be used for screening,
whereas serum ferritin concentration can be used
to confirm diagnosis of iron deficiency. Several
studies have examined the relationship between iron
deficiency and hair loss. Currently, there is insufficient
evidence to recommend screening for iron deficiency
in patients with hair loss on a routine basis and
replacement of iron in the absence of iron deficiency
anemia (12,13). There is also scarce information in
literature about the relationship of the pathogenesis
of TE with vitamin D and zinc deficiency. In this
case-control study we aimed to investigate if there
is any relationship between acute/chronic TE and
anemia, zinc deficiency, and serum vitamin D levels.
Patients and methods
The study was performed in a case-control design.
In order to minimize the effect of seasonal changes
on vitamin D levels, the study was conducted in
winter between November 2008 and March 2009.
All of the patients enrolled in the study were living
in Ankara (central Anatolia), where these months are
considered to be winter, with little exposure to UV
light. The study population consisted of 63 female
patients with TE who had not previously received
any treatment. Dermatological examinations of all
patients were performed by the same dermatologist.
A diagnosis of TE was considered when patients
had increased shedding by history or physical
examination that is performed by hair shedding
continuing at a rate of 100/day, and the hair pull test
that was positive (1,14). In chronic TE, as described
by Whiting, women present with an abrupt onset of
generalized shedding of telogen hairs from the scalp,
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with or without an identifiable trigger, that persists
more than 6 months (6). There is no frontoparietal
hair loss with widening of the central part and these
women characteristically present with a full, thick
head of hair (15).
The patients diagnosed with female pattern hair
loss (FPHL) were excluded from the study (16,17).
In general, these women had widening of the midline
hair part and preservation of the anterior hair line (17).
In order to differentiate TE and FPHL, the subjects
were examined with dermoscopy. No variation in
shaft diameter is a characteristic of acute TE and
no significant variation and no miniaturization are
characteristics of chronic TE. Marked variation in
shaft diameter and miniaturization of follicles are
prominent features of FPHL (17).
Eligible subjects underwent a comprehensive
medical assessment including documentation of
the detailed history, physical examination, and
measurement of the essential laboratory variables.
Exclusion criteria were drug abuse, malignancy,
hypercalcemia, hypocalcemia, hyperparathyroidism,
functional renal or liver abnormalities, systemic lupus
erythematosus, syphilis, and any condition causing
fever. Patients who were on calcium-phosphorus
modifying drugs were also excluded from the study.
Fifty control subjects were chosen from patients who
were referred to our clinic for the treatment of nevus
and had no systemic disease and/or hair shedding.
The Local Ethics Committee approved the study, and
all patients gave informed consent.
Fasting blood samples were obtained by
venipuncture of the large antecubital veins of the
patients without stasis and after a 12-h fasting. The
samples were then centrifuged immediately; the
plasma was separated and stored at –80 °C. In order to
avoid variation, all samples were studied on the same
day and using the same kit. Serum 25-hydroxyvitamin
D3 (25(OH)D3), 1,25(OH)2D3, and bone alkaline
phosphatase (BAP) levels were measured by RIA.
25OH-VIT.D3-RIA-CT kit (Catalog No: KIP1961)
and 1,25(OH)2-VIT.D3-RIA-CT kit (Catalog No:
KIP1921, Biosource, Neville, Belgium) were used.
BAP level was measured by Ostease IRMA kit
(Immunotech, Beckman Coulter, Inc., Fullerton, CA,
USA). Serum hemoglobin, ferritin, zinc, calcium,
phosphate, parathormone, magnesium, and thyroid

stimulating hormone (TSH) levels were measured by
standard laboratory techniques.
Statistical analyses were performed with SPSS
version 11.0 (SPSS Inc, Chicago, IL, USA). All
numerical variables are expressed as the mean ±
standard deviation (SD). Normality of data was
analyzed using a Kolmogorov-Smirnov test and
intergroup differences were analyzed and compared
by means of the independent samples t test. We used
one-way ANOVA to analyze intergroup differences
of more than 2 groups and also used a Tukey test
for post hoc analyses. In the case of nonhomogenic
data, a Mann-Whitney U test was used to analyze
intergroup differences. A Kruskal-Wallis test was
performed for analyzing data of more than 2 groups
with nonhomogenous variability. A chi-square
test and regression analysis were used for defining
risk factors for TE. A P value of less than 0.05 was
considered statistically significant.
Results
The mean age was 29.1 ± 11.9 years in the TE
group and 28.4 ± 9.4 years in the control group.
Twenty-nine of the patients were classified as having
acute TE and 34 as having chronic TE. Demographic
and biochemical parameters are listed in Table 1.
According to analyses comparing the control and TE
groups of any stage, the TE group had significantly
lower hemoglobin and ferritin, and higher 25(OH)
D3 levels (P < 0.0001, 0.001, 0.01, respectively).
A comparison of the 3 groups with each other (no
TE, acute TE, and chronic TE) also revealed that the
acute TE group had the lowest hemoglobin (Table 2,
Figure 1). Ferritin values of both chronic and acute
TE groups were also lower compared to the control
group but were similar with each other (Table 2).
The chronic TE group had the highest serum levels
of 25(OH)D3 (Table 2, Figure 2). Regression analysis
revealed that the presence of anemia (Hb < 12 g/dL)
was a significant risk factor for TE (P < 0.02, OR: 4.3,
CI: 1.01-18.79). We also analyzed data after grouping
patients according to being in the highest and lowest
quadrants for hemoglobin, ferritin, 25(OH)D3, and
1,25(OH)2D3 values. According to these analyses,
patients in the lowest hemoglobin and ferritin
quadrants had higher risks for TE (P < 0.001, OR:
829
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Table 1. Comparison of TE and control groups.

Age (years)
Hemoglobin (g/dL)
Ferritin (ng/mL)
Calcium (mg/dL)
Phosphorus(mg/dL)
iPTH (pg/ml)
Magnesium (mmol/L)
Alkalene Phosphatase (U/L)
Zinc (μg/dL)
TSH (mIU/L)
25(OH)D3 (ng/mL)
1,25(OH)D3 (pg/mL)

TE group
n: 63

Control group
n: 50

P value

29.0 ± 11.9
12.9 ± 1.5
18.4 ± 14.1
9.7 ± 0.4
3.2 ± 0.4
59.2 ± 24.8
0.7 ± 0.08
10.2 ± 4.8
74.2 ± 10.8
1.8 ± 1.0
21.7 ± 10.7
21.9 ± 6.0

28.4 ± 9.3
14.2 ± 1.2
35.5 ± 31.8
9.8 ± 0.3
3.3 ± 0.5
59.7 ± 31.2
0.8 ± 0.07
10.5 ± 4.9
73.5 ± 8.6
1.8 ± 1.1
15.6 ± 15.8
22.8 ± 5.2

NS
< 0.0001
< 0.001
NS
NS
NS
NS
NS
NS
NS
< 0.01
NS

NS: non-significant
iPTH: intact parathyroid hormone
TSH: thyroid stimulating hormone
25(OH)D3: 25-hydroxyvitamin D3
1,25(OH)2D3: 1,25-dihydroxyvitamin D3

Table.2. Comparison of controls and acute and chronic TE groups.
Acute TE group
n: 29
26.9 ± 10.3

Chronic TE group
n: 34
30.9 ± 12.9

Control group
n: 50
28.4 ± 9.3

Hemoglobin (g/dL)

12.7 ± 1.7

13.3 ± 1.0

14.2 ± 1.2

Ferritin (ng/mL)

17.0 ± 12.8

19.6 ± 15.2

35.5 ± 31.8

Calcium (mg/dL)
Phosphorus (mg/dL)
iPTH (pg/mL)
Magnesium (mmol/L)
Alkalene Phosphatase (U/L)
Zinc (μg/dL)
TSH (mIU/L)

9.7 ± 0.4
3.2 ± 0.4
62.4 ± 25.4
0.7 ± 0.07
11.0 ± 5.5
75.0 ± 10.3
1.9 ± 1.3

9.7 ± 0.3
3.1 ± 0.5
56.4 ± 24.3
0.8 ± 0.09
9.6 ± 4.1
73.5 ± 11.2
1.7 ± .7

9.8 ± 0.3
3.3 ± 0.5
59.7 ± 31.2
0.8 ± 0.07
10.5 ± 4.9
73.5 ± 8.6
1.8 ± 1.1

25(OH)D3 (ng/mL)

18.5 ± 9.2

24.4 ± 11.2

15.6 ± 15.8

1,25(OH)D3 (pg/mL)

23.3 ± 4.8

20.8 ± 6.6

22.8 ± 5.2

Age

NS: non-significant
iPTH: intact parathyroid hormone
TSH: thyroid stimulating hormone
25(OH)D3: 25-hydroxyvitamin D3
1,25(OH)2D3: 1,25-dihydroxyvitamin D3
* P values for acute TE vs. control groups
** P values for chronic TE vs. control groups
*** P values for acute TE vs. chronic TE groups

830

P values
NS
< 0.0001*
< 0.01**
< 0.005*
< 0.01**
NS
NS
NS
NS
NS
NS
NS
< 0.05*
< 0.01**
< 0.05***
NS
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P < 0.0001
80.00
25-hydroxy vitamin D3 levels

Hemoglobin (g/dL)

16.00

14.00

12.00

10.00

60.00
P < 0.01
P < 0.05

P < 0.05

40.00

20.00
P < 0.01

8.00

Control Group

Acute TE

Chronic TE

Figure 1. Hemoglobin levels in the control, acute TE, and chronic
TE groups.

2.7, CI: 1.47-5.23 and P < 0.02, OR: 1.9, CI: 1.06-3.48,
respectively), while patients in the highest 25(OH)
D3 quadrant had a significant risk compared to the
lowest quadrant (P < 0.0001, OR: 3.1, CI: 1.54-6.59).
No risk for 1,25(OH)2D3 levels was identified (Table
3). No risk factors specific just for acute or chronic
TE could be identified. No significant differences
for serum zinc levels could be identified in any
stage of statistical analysis. We found no correlation
between ferritin and parathormone, 25(OH)D3,
1,25(OH)2D3, and BAP levels. We stratified all of
the study population into anemic and non-anemic
groups. We found no statistical difference between
these groups in terms of parathormone, 25(OH)D3,
1,25(OH)2D3, BAP, Ca, P, and Mg levels.
Discussion
Excessive telogen hair loss or TE is a problem that
is commonly encountered by clinical dermatologists

Control group

Acute TE

Chronic TE

Figure 2. 25-Hydroxy vitamin D3 levels in the control, acute TE,
and chronic TE groups.

in daily practice. In nearly 33% of cases there is
no identified etiological reason; however, in other
patients usually a pathological condition could be
identified as the underlying cause of TE. These causes
vary from common and easily treatable hormonal
or nutritional problems like thyroid metabolism
defects or zinc deficiency to less common but
severe systemic diseases like systemic lupus, chronic
renal or liver failures, and malignancies or severe
emotional stress. Presence of iron deficiency with
or without anemia was also speculated as a cause of
TE and some studies were conducted on this subject
previously (1-5). According to our findings presence
of anemia was an important risk factor for TE (P <
0.02, OR: 4.3) and both acute and chronic TE groups
had significantly lower hemoglobin values compared
to control patients (Table 2). Similarly we found that
patients with acute or chronic TE had lower ferritin
levels compared to the control group (Table 2). Being
in the lowest hemoglobin and ferritin quadrants was

Table 3. Risk factors for Telogen effluvium.
P-values

Odds ratio

95% CI

Presence of anemia

<0.02

4.3

1.01 – 18.79

Lowest Hb quadrant

<0.001

2.7

1.47 – 5.23

<0.02

1.9

1.06 – 3.48

<0.0001

3.1

1.54 – 6.59

Lowest ferritin quadrant
Highest 25(OH)D3 quadrant
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also identified as a important risk factor for TE (P <
0.001, OR: 2.7 and P < 0.02, OR: 1.9, respectively).
Acute TE patients also seem to have lower
hemoglobin and ferritin values compared to chronic
TE patients. However, these differences were not
statistically significant (Table 2, Figure 1). Supporting
our findings, Deloche et al. reported that a low iron
store defined as low ferritin levels represents a risk
factor for hair loss in non-menopausal women in a
very large population of 5110 women aged between
35 and 60 years (18). Treatment of iron deficiency
was also reported by some authors to decrease
hair shed. In a prospective double-blind, placebocontrolled study Rushton et al. reported a group of
12 female subjects with chronic TE. In their study, 7
subjects received 72 mg iron and 1.5 g L-lysine daily
for 6 months, whereas 5 subjects received placebo.
Subjects receiving therapy experienced a 31%
reduction in the amount of hair shed compared with
a 9% increase in control subjects (19). Similarly in a
prospective cohort study involving 22 female subjects
with chronic TE who received 72 mg iron and 1.5 of
L-lysine daily for 6 months, the mean percentage
of hair in the telogen phase significantly decreased
from 19.5% to 11.3% (15). However, there are also
some studies that neglect iron deficiency anemia as
a cause of TE. In one of these studies, Sinclair et al.
reported a prospective cohort of 194 female subjects,
presenting with diffuse telogen hair loss for 6 months
or longer, and found that 12 (6%) had serum ferritin
concentrations less than or equal to 20 ng/mL. Three
of these 12 patients had chronic TE and they were
treated with iron supplementation for 3 to 6 months
until their serum ferritin concentrations rose above
20 ng/mL. However, no change in hair status after
treatment was observed (7). Kantor et al. also reported
that ferritin levels of patients with androgenetic
alopecia and alopecia areata were significantly lower
than in controls without hair loss; however, there is no
difference between chronic TE patients and control
subjects (14). Bregy and Trueb similarly reported
that there is no association between serum ferritin
levels >10 μg/L and hair loss activity in women (20).
Authors who state that there is a link between iron
deficiency and TE usually think that, in cases of low
iron depots, hair follicles that have shed their hair at
the end of telogen may temporarily fail to re-enter
anagen, leading to a slow onset diffuse hair loss (5).
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The relationship between iron deficiency with no
anemia or only mild anemia and chronic diffuse hair
loss is, however, more complex and controversial
(21).
Another commonly encountered problem that
may cause anemia in women is zinc deficiency. There
is also common belief that zinc deficiency is associated
with hair loss (1,22,23). In the present study, we
failed to find a significant difference in serum zinc
levels of acute and chronic telogen effluvium groups
compared to controls. However, there are also some
contradictory reports that may support our findings,
which also could not present any association between
zinc deficiency and TE (23,24).
An interesting result that we found was increased
25(OH)D3 levels in patients with TE. Both acute
and chronic TE patients had higher serum levels
of 25(OH)D3 compared to control subjects (Table
2, Figure 2). Those having a serum level of 25(OH)
D3 in the highest quadrant also had a significantly
increased risk for TE compared to those in the lowest
quadrant (P < 0.0001, OR: 3.1). We did not observe
any statistically significant difference in the levels
of calcium, phosphate, magnesium, bone alkaline
phosphatase, 1,25(OH)2D3, or parathormone levels.
It is well known that vitamin D has an important
role in hair growth. Epidermis is the main site for
synthesis of 25(OH)D3, mediated by sunlight (8).
The epidermal keratinocytes, in addition to many
other cells residing in the skin, have the required
enzymes to metabolize vitamin D, and keratinocytes
also contain the receptor for 1,25(OH)2D3 (25). The
effects of 1,25(OH)2D3 on keratinocytes show a shift
from the hyperproliferative cell compartment toward
the differentiating cell compartment (26). Alopecia
was noted in vitamin D receptor (VDR) knockout
mice, and this is often, but not invariably, found in
patients of some vitamin D-dependent rickets type
II (VDDR-II) kindreds (27). Depending on these
previous findings, one expects to observe decreased
levels of 25(OH)D3 in patients with TE. However,
this is not the case in our study and patients with
chronic TE seem to have higher levels of 25(OH)
D3 compared to both acute TE patients and control
subjects. It seems that there is a trend of increase
from control subjects to acute and chronic TE
patients (Table 2, Figure 2). We think that this might
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not be the cause but rather a secondary response to
the development of TE. We do not know the reason
for the increase in 25(OH)D3levels in TE patients.
Telogen hair follicles do not show melanin synthesis
in their undifferentiated melanocytes/melanoblasts,
which may ultimately increase UV exposure and
vitamin D synthesis in the skin (28).

In conclusion, iron deficiency anemia appears
to be an important risk factor for development of
TE in otherwise healthy female patients. We think
that the increase in serum 25(OH)D3 levels is a
compensatory response to TE and any possible effect
of this increase should be assessed further by clinical
and experimental studies.
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